Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | XDH | P47989 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.50 |
| ▸ | TLR4 | O00206 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17951858 | 0.86 | FAAH (0.54) | ALDH1A1XDHKDM4EFAAHRAB9A | |
| SCHEMBL23902532 | 0.84 | XDH (0.51) | ALDH1A1XDHKDM4ERAB9AMAPT | |
| SCHEMBL5355510 | 0.82 | FAAH (0.51) | ALDH1A1XDHKDM4EFAAHRAB9A | |
| SCHEMBL1590095 | 0.82 | FAAH (0.55) | ALDH1A1XDHKDM4EFAAHRAB9A | |
| SCHEMBL1490560 | 0.81 | FAAH (0.50) | ALDH1A1XDHKDM4EFAAHRAB9A | |
| SCHEMBL4464221 | 0.81 | XDH (0.49) | ALDH1A1XDHKDM4ERAB9AMAPT | |
| SCHEMBL1535700 | 0.81 | FAAH (0.54) | ALDH1A1XDHKDM4EFAAHRAB9A | |
| SCHEMBL11027841 | 0.81 | XDH (0.49) | ALDH1A1XDHKDM4ERAB9AMAPT | |
| SCHEMBL3612583 | 0.81 | FAAH (0.54) | XDHKDM4EFAAHRAB9ACES1 | |
| Hydrochloric Acid SCHEMBL23320558 | 0.81 | FAAH (0.54) | XDHKDM4EFAAHRAB9ACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | disclosed |
| CN-117924156-A | Synthesis method of aza-aryl alcohol compound and chiral alpha-hydroxycarboxylic acid | 赣南师范大学 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230174689-A1 | POLYMER | SUMITOMO CHEMICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| US-20230174689-A1 | POLYMER | SUMITOMO CHEMICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| US-20230174689-A1 | POLYMER | SUMITOMO CHEMICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| EP-4116303-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220343946-A1 | DATA STORAGE METHOD AND COMPOSITION | SUMITOMO CHEMICAL CO., LTD. (JP) | 2022-10-27 | — | — | US | disclosed |
| CN-114503199-A | Data storage method and composition | 住友化学株式会社 | 2022-05-13 | — | — | CN | disclosed |
| EP-2314598-A1 | Inhibitors of Hepatitis C virus NS3 serine protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2008129129-A1 | HETEROCYCLIC PHENYL CARBAMATES AS NOVEL FAAH-INHIBITORS | KUOPION YLIOPISTO (FI) | 2008-10-30 | — | — | WO | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1529093-B1 | GAS ODORISATION USING PHENOLS AND/OR PHENOL ETHERS | SYMRISE GMBH & CO KG (DE) | 2007-05-16 | — | — | EP | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-4822809-A | ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1989-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | ALDH1A1 135/4885XDH 30/4885KDM4E 4021/4885 |
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | CTSV, CTSL, CTSE | ALDH1A1 1016/4885XDH 1307/4885KDM4E 3409/4885 |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | ALDH1A1 424/4885XDH 160/4885KDM4E 200/4885 |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | HPN, PRSS1, PRSS3 | ALDH1A1 3201/4885XDH 1016/4885KDM4E 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.